Chronic Pain and DepressionAmong Primary Care Patients Treated with Buprenorphine

Journal of General Internal Medicine

Volumn 30, Issue 7, 2015, Pages 935-941

  Stein, Michael D ^a,b   Herman, Debra S ^a,b   Bailey, Genie L ^b,c   Straus, John ^b   Anderson, Bradley J ^a   Uebelacker, Lisa A ^a,b   Weisberg, Risa B ^b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c Stanley Street Treatment and Resources ^*  (United States)

Author keywords

buprenorphine; chronic pain; depression

Indexed keywords

ALCOHOL; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; CANNABIS; COCAINE; GABAPENTIN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL;

ADULT; ALCOHOLISM; ARTICLE; CANNABIS ADDICTION; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CHRONIC PAIN; COCAINE DEPENDENCE; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; FEMALE; HEALTH CENTER; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; MULTICENTER STUDY; OPIATE ADDICTION; PAIN ASSESSMENT; PAIN SEVERITY; PATIENT HEALTH QUESTIONNAIRE 2; PRIMARY MEDICAL CARE; RISK FACTOR; SELF REPORT; SUBSTANCE USE; SYMPTOM; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; EMPLOYMENT; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PRIMARY HEALTH CARE; PROCEDURES; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGICAL RATING SCALE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; BUPRENORPHINE; CHRONIC PAIN; CROSS-SECTIONAL STUDIES; DEPRESSION; DIAGNOSIS, DUAL (PSYCHIATRY); EMPLOYMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ENGLAND; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT; PRIMARY HEALTH CARE; PSYCHIATRIC STATUS RATING SCALES;

EID: 84931574030     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-015-3212-y     Document Type: Article

References (66)

1. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795 ed. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
2. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2:CD002207.
3. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289(18):2370–8.
4. Sheu R, Lussier D, Rosenblum A, et al. Prevalence and characteristics of chronic pain in patients admitted to an outpatient drug and alcohol treatment program. Pain Med. 2008;9(7):911–7.
5. Karasz A, Zallman L, Berg K, Gourevitch M, Selwyn P, Arnsten JH. The experience of chronic severe pain in patients undergoing methadone maintenance treatment. J Pain Symptom Manage. 2004;28(5):517–25.
6. Jamison RN, Kauffman J, Katz NP. Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage. 2000;19(1):53–62.
7. Peles E, Schreiber S, Gordon J, Adelson M. Significantly higher methadone dose for methadone maintenance treatment (MMT) patients with chronic pain. Pain. 2005;113(3):340–6.
8. Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. J Clin Psychiatry. 2009;70(9):1213–1218. PMCID: PMC2760669.
9. Brands B, Blake J, Sproule B, Gourlay D, Busto U. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend. 2004;73(2):199–207.
10. Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphreys K. Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. Drug Alcohol Depend. 2004;73(1):23–31.
11. Rosenblum A, Parrino M, Schnoll SH, et al. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend. 2007;90(1):64–71.
12. Barry DT, Savant JD, Beitel M, et al. Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict. 2013;22(3):212–217. PMCID: PMC3641684.
13. Mark TL, Dilonardo J, Vandivort R, Miller K. Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine. J Subst Abuse Treat. 2013;44(5):481–7.
14. Tsui JI, Herman DS, Kettavong M, Anderson BJ, Stein MD. Escitalopram is associated with reductions in pain severity and pain interference in opioid dependent patients with depressive symptoms. Pain. 2011;152(11):2640–2644. PMCID: PMC3235744.
15. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998;280(2):147–51.
16. Portenoy RK, Ugarte C, Fuller I, Haas G. Population-based survey of pain in the United States: differences among white, African American, and Hispanic subjects. J Pain. 2004;5(6):317–28.
17. Barry DT, Beitel M, Joshi D, Schottenfeld RS. Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment. Am J Addict. 2009;18(2):117–21. PMCID: PMC2679697.
18. Silberbogen AK, Janke EA, Hebenstreit C. A closer look at pain and hepatitis C: preliminary data from a veteran population. J Rehabil Res Dev. 2007;44(2):231–44.
19. Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep. 2003;7(5):342–7.
20. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain. 2008;24(6):479–96.
21. Blondell RD, Ashrafioun L, Dambra CM, Foschio EM, Zielinski AL, Salcedo DM. A Clinical Trial Comparing Tapering Doses of Buprenorphine with Steady Doses for Chronic Pain and Co-existent Opioid Addiction. J Addict Med. 2010;4(3):140–6. PMCID: PMC2931595.
22. Jones JD, Sullivan MA, Manubay J, Vosburg SK, Comer SD. The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine/naloxone. Neuropsychopharmacology. 2011;36(2):411–22. PMCID: PMC3055661.
23. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12(5):379–84.
24. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. Addict Dis. 2013;32(1):68–78. PMCID: PMC3604999.
25. Potter JS, Chakrabarti A, Domier CP, Hillhouse MP, Weiss RD, Ling W. Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network. J Subst Abuse Treat. 2010;38(Suppl 1):S80–86. PMCID: PMC3150507.
26. Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38(11):2724–8.
27. Barry DT, Beitel M, Cutter CJ, et al. Allopathic, complementary, and alternative medical treatment utilization for pain among methadone-maintained patients. Am J Addict. 2009;18(5):379–85. PMCID: PMC2777756.
28. Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18(4):331–7.
29. Rounsaville B, Weissman M, Crits-Christoph K, Wilber C, Kleber H. Diagnosis and symptoms of depression in opiate addicts: course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39(2):151–6.
30. Brooner R, King V, Kidorf M, Schmidt C Jr, Bigelow G. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry. 1997;54(1):71–80.
31. Kidorf M, Disney ER, King VL, Neufeld K, Beilenson PL, Brooner RK. Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug Alcohol Depend. 2004;74(2):115–22.
32. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biol Psychiatry. 2004;56(10):793–802.
33. Stein MD, Herman DS, Kettavong M, et al. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010;39(2):157–66. PMCID: PMC2910850.
34. Potter JS, Prather K, Weiss RD. Physical pain and associated clinical characteristics in treatment-seeking patients in four substance use disorder treatment modalities. Am J Addict. 2008;17(2):121–5.
35. Larson MJ, Paasche-Orlow M, Cheng DM, Lloyd-Travaglini C, Saitz R, Samet JH. Persistent pain is associated with substance use after detoxification: a prospective cohort analysis. Addiction. 2007;102(5):752–60.
36. Fordyce WE, Shelton JL, Dundore DE. The modification of avoidance learning pain behaviors. J Behav Med. 1982;5(4):405–14.
37. Vlaeyen JW, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000;85(3):317–32.
38. Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: a diathesis-stress framework. Psychol Bull. 1996;119:95–110.
39. Nakao M, Yano E. Somatic symptoms for predicting depression: one-year follow-up study in annual health examinations. Psychiatry Clin Neurosci. 2006;60(2):219–25.
40. Barkow K, Heun R, Ustun TB, Maier W. Identification of items which predict later development of depression in primary health care. Eur Arch Psychiatry Clin Neurosci. 2001;251(Suppl 2):II21–26.
41. Grotle M, Foster NE, Dunn KM, Croft P. Are prognostic indicators for poor outcome different for acute and chronic low back pain consulters in primary care? Pain. 2010;151(3):790–7. PMCID: PMC3398128.
42. Langley PC. The societal burden of pain in Germany: health-related quality-of-life, health status and direct medical costs. J Med Econ. 2012;15(6):1201–15.
43. Gatchel RJ, Bernstein D, Stowell AW, Pransky G. Psychosocial differences between high-risk acute vs. chronic low back pain patients. Pain Pract. 2008;8(2):91–7.
44. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113(1–2):9–19.
45. Landmark T, Romundstad P, Dale O, Borchgrevink PC, Kaasa S. Estimating the prevalence of chronic pain: validation of recall against longitudinal reporting (the HUNT pain study). Pain. 2012;153(7):1368–73.
46. Dworkin RH, Turk DC, Peirce-Sandner S, et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain. 2012;153(6):1148–58.
47. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–38.
48. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10(2):77–84.
49. Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41(11):1284–92.
50. Holm S. A simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65–70.
51. Karp JF, Scott J, Houck P, Reynolds CF 3rd, Kupfer DJ, Frank E. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005;66(5):591–7.
52. Ohayon MM. Specific characteristics of the pain/depression association in the general population. J Clin Psychiatry. 2004;65(Suppl 12):5–9.
53. Tang NK, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med. 2006;36(5):575–86.
54. Meeks TW, Dunn LB, Kim DS, et al. Chronic pain and depression among geriatric psychiatry inpatients. Int J Geriatr Psychiatry. 2008;23(6):637–42.
55. Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain. 2004;107(1–2):54–60.
56. Gameroff MJ, Olfson M. Major depressive disorder, somatic pain, and health care costs in an urban primary care practice. J Clin Psychiatry. 2006;67(8):1232–9.
57. Currie SR, Wang J. More data on major depression as an antecedent risk factor for first onset of chronic back pain. Psychol Med. 2005;35(9):1275–82.
58. Melloh M, Elfering A, Egli Presland C, et al. Predicting the transition from acute to persistent low back pain. Occup Med (Lond). 2011;61(2):127–31.
59. Harkapaa K, Jarvikoski A, Mellin G, Hurri H, Luoma J. Health locus of control beliefs and psychological distress as predictors for treatment outcome in low-back pain patients: results of a 3-month follow-up of a controlled intervention study. Pain. 1991;46(1):35–41.
60. Mercier A, Auger-Aubin I, Lebeau JP, et al. Evidence of prescription of antidepressants for non-psychiatric conditions in primary care: an analysis of guidelines and systematic reviews. BMC Fam Pract. 2013;14:55. PMCID: PMC3648410.
61. Kerns RD, Sellinger J, Goodin BR. Psychological treatment of chronic pain. Annu Rev Clin Psychol. 2011;7:411–34.
62. Barry DT, Savant JD, Beitel M, et al. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone. J Addict Med. 2012;6(4):274–9. PMCID: PMC3492534.
63. Barry DT, Bernard MJ, Beitel M, Moore BA, Kerns RD, Schottenfeld RS. Counselors’ Experiences Treating Methadone-maintained Patients with Chronic Pain: A Needs Assessment Study. J Addict Med. 2008;2(2):108–11.
64. Ilgen MA, Trafton JA, Humphreys K. Response to methadone maintenance treatment of opiate dependent patients with and without significant pain. Drug Alcohol Depend. 2006;82(3):187–93.
65. Currie SR, Hodgins DC, Crabtree A, Jacobi J, Armstrong S. Outcome from integrated pain management treatment for recovering substance abusers. J Pain. 2003;4(2):91–100.
66. Clark MR, Stoller KB, Brooner RK. Assessment and management of chronic pain in individuals seeking treatment for opioid dependence disorder. Can J Psychiatry. 2008;53(8):496–508.